Immunomodulatory active salamander peptides and uses thereof
By preparing a novel salamander peptide GIGFFP and docking it with the TLR4/MD2 receptor molecule, the problem of weak immune targeting of existing salamander peptides was solved, achieving high binding activity and easy absorption of immunomodulatory effects, and enhancing cell function and nutritional value.
CN122145568APending Publication Date: 2026-06-05NANTONG YIMA BIOPHARMACEUTICAL TECH CO LTD +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- NANTONG YIMA BIOPHARMACEUTICAL TECH CO LTD
- Filing Date
- 2026-04-20
- Publication Date
- 2026-06-05
Smart Images
Figure CN122145568A_ABST
Abstract
The application relates to the technical field of functional food development, in particular to an immunoregulatory active newt peptide and application thereof. A new newt peptide GIGFFP is disclosed for the first time, the sequence of which is a brand-new structure which has not been reported in anderson's origin, and the peptide segment is not disclosed in the contrast documents, and no related sequence is recorded. The peptide is docked with a TLR4 / MD2 (PDB ID: 5IJD) receptor molecule for the first time, the key sites are combined through Pi-Pi interaction and van der waals force, and the immunoregulatory molecular mechanism is determined. The newt peptide has the advantages of high nutritional components, small molecular weight, easy absorption and immunoregulatory activity, provides theoretical support for further development of immunoregulatory functional food by using the newt peptide, and improves the development value of the anderson.
Need to check novelty before this filing date? Find Prior Art